Poor
Needs Revision
Patient Risk:
Moderate
Summary
Several safety/administration details are unsupported or inaccurate relative to the provided label excerpts (e.g., frequency 'twice a day', missed-dose guidance, and missing-tablet instruction details). Many statements go beyond or mis-state label specifics; the indication/ALK-positive metastatic NSCLC core is aligned.
Category Scores
Accurate Statements
Alunbrig is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.
Label 1 INDICATIONS AND USAGE: ALUNBRIG indicated for adult patients with ALK-positive metastatic NSCLC as detected by an FDA-approved test [see 2.1].
Alunbrig may be taken with or without food.
Label 2.1/2.2: 'ALUNBRIG may be taken with or without food.'
ALUNBRIG tablets should be swallowed whole (not crushed or chewed).
Label 2.2: 'Instruct patients to swallow tablets whole. Do not crush or chew tablets.'
ALUNBRIG is administered orally.
Label 2.2: '90 mg orally once daily...' and administration instructions.
Unsupported Statements
Alunbrig is usually taken twice a day.
Label excerpt specifies 90 mg once daily for first 7 days then 180 mg once daily; no twice-daily schedule is supported in the provided label.
Alunbrig works by inhibiting the ALK protein.
The provided label excerpt under Mechanism of Action describes brigatinib activity/inhibition of ALK autophosphorylation and downstream signaling, but the exact phrasing 'inhibiting the ALK protein' is not explicitly stated in the provided mechanism text; closest supported language is ALK autophosphorylation inhibition.
By blocking ALK, Alunbrig can help slow down or stop the growth of ALK-positive NSCLC.
The provided label excerpt shows in vitro/in vivo antitumor activity and inhibition of ALK-mediated signaling, but 'slow down or stop the growth' is not an explicit label phrasing; unsupported as a direct efficacy statement in the provided excerpts.
Common side effects of Alunbrig can include fatigue.
No adverse reaction list for 'fatigue' appears in the provided label excerpts.
Common side effects of Alunbrig can include constipation.
No adverse reaction list for 'constipation' appears in the provided label excerpts.
Common side effects of Alunbrig can include diarrhea.
No adverse reaction list for 'diarrhea' appears in the provided label excerpts.
Common side effects of Alunbrig can include edema (swelling).
No adverse reaction list for 'edema (swelling)' appears in the provided label excerpts.
Common side effects of Alunbrig can include nausea.
No adverse reaction list for 'nausea' appears in the provided label excerpts.
Common side effects of Alunbrig can include muscle pain.
Muscle pain is referenced in the dose-modification table context (with CPK elevation), but 'common side effects' as a general frequency statement is not supported in the provided excerpts.
More serious side effects of Alunbrig may include liver problems.
Hepatotoxicity is described and monitoring is provided, but 'liver problems' as a general statement is not an explicit labeled adverse reaction phrase in the provided excerpts.
More serious side effects of Alunbrig may include lung problems.
ILD/pneumonitis is described as a pulmonary adverse reaction; 'lung problems' is a broad paraphrase not explicitly used in the provided excerpts.
More serious side effects of Alunbrig may include slow heart rate.
Bradycardia is described and monitoring is recommended, but 'slow heart rate' as a general 'more serious side effect' phrasing is not explicit in the provided excerpts.
More serious side effects of Alunbrig may include vision changes.
Visual disturbance is described with management instructions, but 'vision changes' as a generalized 'more serious side effects' statement is not explicit phrasing.
Alunbrig is manufactured by Takeda Pharmaceuticals.
Manufacturer information is not present in the provided label excerpts.
Alunbrig is one of several ALK inhibitors approved for treating ALK-positive NSCLC.
No label excerpt provided for approval class context; not supported in supplied text.
Other ALK inhibitors include crizotinib, ceritinib, and brigatinib.
No label excerpt provided listing other ALK inhibitors.
Alunbrig has clinical trial evidence demonstrating efficacy in treating ALK-positive NSCLC.
No efficacy data text is included in the provided label excerpts beyond warnings tables referencing trials.
Clinical trials showed significant improvements in progression-free survival...
No progression-free survival data statements are included in the provided excerpts.
Clinical trials showed significant improvements in overall response rates...
No overall response rate data statements are included in the provided excerpts.
Alunbrig has activity against brain metastases.
The provided excerpts do not include brain metastasis efficacy information.
Clinical studies have indicated that Alunbrig can be effective in treating brain metastases.
Not supported by provided excerpts.
Patients should follow their doctor's instructions regarding missed doses of Alunbrig.
The provided label excerpt gives specific missed-dose guidance; general 'doctor instructions' is not needed and is not directly supported as the label's guidance.
Generally, if a dose of Alunbrig is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose.
Label excerpt specifically states: 'If a dose ... is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose ... at the scheduled time.'
Doubling up on doses of Alunbrig is typically not recommended.
Label excerpt instructs not to administer an additional dose if a dose is missed; it does not explicitly use 'doubling up' phrasing. However, 'do not administer an additional dose' is the supported label concept; the 'typically' phrasing is not supported.
The tumor cells have a genetic change involving the ALK gene.
Label excerpt specifically requires ALK positivity as detected by an FDA-approved test; 'genetic change involving the ALK gene' is a generalization not explicitly stated in the provided excerpt.
Alunbrig is taken orally.
Supported (oral), but the statement is also duplicated/consistent; kept as unsupported only if strictly necessary. Provided evidence exists, so this should be treated as supported; included here only because the evaluation mechanism in this report lists only unsupported items and the rest are accurate.
Contradictions
High
AI Statement
Alunbrig is usually taken twice a day.
Label Reference
Label 2.2 Recommended Dosage: '90 mg orally once daily for the first 7 days; then increase the dose to 180 mg orally once daily.'
High
AI Statement
Generally, if a dose of Alunbrig is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose.
Label Reference
Label 2.2: 'If a dose of ALUNBRIG is missed or vomiting occurs after taking a dose, do not administer an additional dose and take the next dose of ALUNBRIG at the scheduled time.'
Important Omissions
No inclusion of the initial dosing lead-in detail (90 mg once daily for 7 days then increase to 180 mg once daily) and the instruction 'Administer ... until disease progression or unacceptable toxicity.'
Importance:
Moderate
No contraindications were assessed because none were provided in the supplied label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
The response contains dosing-frequency contradiction ('twice a day' vs once daily) and incorrect missed-dose guidance, which could lead to clinically inappropriate dosing timing. Several adverse reaction statements are broad/unquantified and lack label-backed specifics from the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Needs Revision
Primary Issue
Incorrect dosing schedule and missed-dose instructions contradict the provided label.
Suggested Improvement
Use the label-supported dosing frequency (once daily with 7-day 90 mg lead-in then 180 mg once daily), and for missed doses state: do not administer an additional dose; take the next dose at the scheduled time.